Jazz Pharmaceuticals (JAZZ) Reit Buy At BofA After Positive Ph3 Results
Tweet Send to a Friend
BofA/Merrill Lynch analyst Jason Gerberry reiterated a Buy rating and $163.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
